As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
The global market for biosimilar is being driven by the rising geriatric population worldwide. Infliximab is the leading molecule segment, which holds the majority of the market share of biosimilar. In addition to this, autoimmune diseases are the most common chronic disease, which is further enhancing the market for biosimilar. The market growth has been primarily driven by the launch of new products and an increasing diagnosis of particular pathologies. The market for biosimilar is being further propelled due to the product offering a cost-effective alternative to stakeholders like physicians and patients, along with ensuring a better access to medication for the patients. The growing R&D activities in the industry is further propelling the market growth.
Pfizer Inc. (NYSE: PFE), a key player in the biosimilar industry, announced in November 2020 that the FDA had approved the company’s ABRILADA™(adalimumab-afzb) as a biosimilar to Humira® (adalimumab). This biosimilar will aid in the treatment of rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, adult Crohn's disease, ankylosing spondylitis, ulcerative colitis, and plaque psoriasis. Such approvals are expected to further expand the market growth.
Market Analysis by Molecule, Type of Manufacturing, Indication, and Region:
Key Findings of the Report:
Key Offerings of the Report:
Pfizer Inc., Celltrion Inc., Novartis AG, Merck Sharp & Dohme Corp., Eli Lilly and Company., Samsung Bioepis, and Accord-UK Ltd., among others are the key players in the global biosimilar market. The EMR report looks into the capacity, market share, and latest developments of these major players like plant turnarounds, mergers and acquisitions, and capacity expansions.
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Expert Market Research
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.